IntroductionThe purpose of this supplement is to provide clinicians with a better understanding of the pathophysiology and management of OAB. Each article provides practical information to the physician treating urinary incontinence and OAB symptoms in clinical practice. This information will be useful in making sound therapeutic decisions based on the most current data available on urinary incontenence and OAB.Based on a satellite symposium held just prior to the American Urological Association 2001 Annual Meeting.This supplement is supported by an unrestricted educational grant from Watson Urology, a division of Watson Pharma, Inc.
EV/pembrolizumab under review in China for advanced urothelial carcinoma
March 28th 2024The sBLA is supported by findings from the phase 3 EV-302 trial, which showed that EV/pembrolizumab extended overall survival and progression-free survival vs platinum-based chemotherapy in patients with advanced urothelial carcinoma.
Potential code for prior authorizations on AMA CPT Editorial Panel meeting agenda
March 28th 2024"Good public and economic policy must align costs, benefits, and incentives; currently, all costs are incurred by physician practices, and all financial savings and benefits from prior authorization accrue to health insurance plans, leading to perverse incentives,” says Alex Shteynshlyuger, MD.